Beconase 50 mikrogram/dosis næsespray, suspension الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

beconase 50 mikrogram/dosis næsespray, suspension

paranova danmark a/s - beclometasondipropionatmonohydrat - næsespray, suspension - 50 mikrogram/dosis

Dysport 500 enheder pulver til injektionsvæske, opløsning الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

dysport 500 enheder pulver til injektionsvæske, opløsning

paranova danmark a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 500 enheder

Duovent 1,25 + 0,5 mg/behol. inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

duovent 1,25 + 0,5 mg/behol. inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder

paranova danmark a/s - fenoterolhydrobromid, ipratropiumbromid - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 1,25 + 0,5 mg/behol.

Imbruvica الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.